Literature DB >> 9260010

Low incidence of the oculocardiac reflex and postoperative nausea and vomiting in adults undergoing strabismus surgery.

M R Tramèr1, T Fuchs-Buder, A Sansonetti, K Rifat.   

Abstract

PURPOSE: To investigate the incidence of the oculocardiac reflex (OCR), and of postoperative nausea and vomiting (PONV) in adults undergoing strabismus surgery.
METHODS: Adults (18-86 yr) undergoing inpatient strabismus surgery received 10 micrograms.kg-1 atropine and 10 micrograms.kg-1 altentanil iv and were randomly allocated to: (A) 5 mg.kg-1 thiopentone iv, isoflurane/N2O maintenance; (B) 3 mg.kg-1 propofol iv, propofol/N2O maintenance (10-14 mg.kg-1.hr-1); 3 mg.kg-1 propofol iv, propofol/air/O2 maintenance (10-14 mg.kg-1.hr-1). Analyses were with the number-needed-to-treat/harm.
RESULTS: In 97 adults the absolute risk of OCR (13-20%) and PONV (21-31% after 24 hr) was low, with no differences between groups. Number-needed-to-treat to prevent PONV with propofol with or without N2O compared with thiopentone-isoflurane was 7 to 11. Number-needed-to-harm for one OCR with propofol compared with thiopentone-isoflurane was 17.
CONCLUSION: Adults undergoing strabismus surgery with prophylactic atropine had a low risk of OCR and PONV, independent of the anaesthetic technique used.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9260010     DOI: 10.1007/BF03013159

Source DB:  PubMed          Journal:  Can J Anaesth        ISSN: 0832-610X            Impact factor:   5.063


  3 in total

Review 1.  The Oculocardiac Reflex: A Review.

Authors:  Robert W Arnold
Journal:  Clin Ophthalmol       Date:  2021-06-24

2.  Does Topical Proparacaine Improve Postoperative Comfort After Strabismus Surgery?

Authors:  Robert W Arnold; Aleah N Bond
Journal:  Clin Ophthalmol       Date:  2019-11-20

3.  Ramosetron versus ondansetron for postoperative nausea and vomiting in strabismus surgery patients.

Authors:  Jin Joo; Shinhye Park; Hue Jung Park; Sun Young Shin
Journal:  BMC Anesthesiol       Date:  2016-07-22       Impact factor: 2.217

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.